Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease
AbstractDiabetic kidney disease (DKD) is the main complication in diabetes mellitus (DM) and the main cause of end-stage kidney disease worldwide. However, sodium glucose cotransporter 2 (SGLT2) inhibition, glucagon-like peptide-1 (GLP-1) receptor agonist, mineralocorticoid receptor antagonists and...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Drug Delivery |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/10717544.2022.2160518 |
| _version_ | 1797260958311120896 |
|---|---|
| author | Xian Chen Wenni Dai Hao Li Zhe Yan Zhiwen Liu Liyu He |
| author_facet | Xian Chen Wenni Dai Hao Li Zhe Yan Zhiwen Liu Liyu He |
| author_sort | Xian Chen |
| collection | DOAJ |
| description | AbstractDiabetic kidney disease (DKD) is the main complication in diabetes mellitus (DM) and the main cause of end-stage kidney disease worldwide. However, sodium glucose cotransporter 2 (SGLT2) inhibition, glucagon-like peptide-1 (GLP-1) receptor agonist, mineralocorticoid receptor antagonists and endothelin receptor A inhibition have yielded promising effects in DKD, a great part of patients inevitably continue to progress to uremia. Newly effective therapeutic options are urgently needed to postpone DKD progression. Recently, accumulating evidence suggests that targeted drug delivery strategies, such as macromolecular carriers, nanoparticles, liposomes and so on, can enhance the drug efficacy and reduce the undesired side effects, which will be a milestone treatment in the management of DKD. The aim of this article is to summarize the current knowledge of targeted drug delivery strategies and select the optimal renal targeting strategy to provide new therapies for DKD. |
| first_indexed | 2024-03-08T23:32:02Z |
| format | Article |
| id | doaj.art-ae9a862c82f74fd0bb1d2757b2ec9bec |
| institution | Directory Open Access Journal |
| issn | 1071-7544 1521-0464 |
| language | English |
| last_indexed | 2024-04-24T23:33:35Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Drug Delivery |
| spelling | doaj.art-ae9a862c82f74fd0bb1d2757b2ec9bec2024-03-15T14:22:17ZengTaylor & Francis GroupDrug Delivery1071-75441521-04642023-12-0130110.1080/10717544.2022.2160518Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney diseaseXian Chen0Wenni Dai1Hao Li2Zhe Yan3Zhiwen Liu4Liyu He5Department of Nephrology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of ChinaDepartment of Nephrology, Hunan Key Lab of Kidney Disease and Blood Purification, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of ChinaDepartment of Nephrology, Hunan Key Lab of Kidney Disease and Blood Purification, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of ChinaDepartment of Nephrology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of ChinaDepartment of Nephrology, Hunan Key Lab of Kidney Disease and Blood Purification, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of ChinaDepartment of Nephrology, Hunan Key Lab of Kidney Disease and Blood Purification, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of ChinaAbstractDiabetic kidney disease (DKD) is the main complication in diabetes mellitus (DM) and the main cause of end-stage kidney disease worldwide. However, sodium glucose cotransporter 2 (SGLT2) inhibition, glucagon-like peptide-1 (GLP-1) receptor agonist, mineralocorticoid receptor antagonists and endothelin receptor A inhibition have yielded promising effects in DKD, a great part of patients inevitably continue to progress to uremia. Newly effective therapeutic options are urgently needed to postpone DKD progression. Recently, accumulating evidence suggests that targeted drug delivery strategies, such as macromolecular carriers, nanoparticles, liposomes and so on, can enhance the drug efficacy and reduce the undesired side effects, which will be a milestone treatment in the management of DKD. The aim of this article is to summarize the current knowledge of targeted drug delivery strategies and select the optimal renal targeting strategy to provide new therapies for DKD.https://www.tandfonline.com/doi/10.1080/10717544.2022.2160518Diabetic kidney diseasediabetes mellitustargeted drug deliverynanoparticleliposome |
| spellingShingle | Xian Chen Wenni Dai Hao Li Zhe Yan Zhiwen Liu Liyu He Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease Drug Delivery Diabetic kidney disease diabetes mellitus targeted drug delivery nanoparticle liposome |
| title | Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease |
| title_full | Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease |
| title_fullStr | Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease |
| title_full_unstemmed | Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease |
| title_short | Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease |
| title_sort | targeted drug delivery strategy a bridge to the therapy of diabetic kidney disease |
| topic | Diabetic kidney disease diabetes mellitus targeted drug delivery nanoparticle liposome |
| url | https://www.tandfonline.com/doi/10.1080/10717544.2022.2160518 |
| work_keys_str_mv | AT xianchen targeteddrugdeliverystrategyabridgetothetherapyofdiabetickidneydisease AT wennidai targeteddrugdeliverystrategyabridgetothetherapyofdiabetickidneydisease AT haoli targeteddrugdeliverystrategyabridgetothetherapyofdiabetickidneydisease AT zheyan targeteddrugdeliverystrategyabridgetothetherapyofdiabetickidneydisease AT zhiwenliu targeteddrugdeliverystrategyabridgetothetherapyofdiabetickidneydisease AT liyuhe targeteddrugdeliverystrategyabridgetothetherapyofdiabetickidneydisease |